Pune: Suryadatta s Conference To Explore AI s Impact On Healthcare And To Honour Doctors freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.
MUMBAI, India
As India launches an ambitious effort to vaccinate 300 million people against the coronavirus within six months, it is employing two vaccines both manufactured domestically but approved under very different circumstances.
One is CoviShield, the vaccine developed by Britain’s AstraZeneca and Oxford University, which clinical trials show is about 70% effective in preventing COVID-19 and is being manufactured in India by the Serum Institute, the country’s largest drugmaker.
The other is Covaxin, developed by an Indian company in conjunction with the government but whose performance in late-stage clinical trials has yet to be published. Health authorities nevertheless approved the vaccine for “restricted emergency use.”